Clinical Trial Update: Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of crizanlizumab to placebo in adolescents and adults with sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Crizanlizumab (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease (SCD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-01-08